RPG group company, RPG Life Sciences, today said that it has commercialised its second biotech immunosuppressant API Sirolimus.
Immunosuppressants like Sirolimus are used in organ transplant patients to prevent organ rejection by the body, the company said in a press release issued here.
The end-to-end Sirolimus technology has been developed through an in-house R&D effort. The formulation of Sirolimus is under development and will be manufactured at the company's MHRA-approved and USFDA approvable immunosuppressant formulations facility, the release said.
The patent of this product expires in early-2014.
"We are one of the two companies from India manufacturing this product. RPG Life Sciences has always focused on biotechnology as one of its growth drivers," the company's Managing Director, Arvind Vasudeva, said.
After Cyclosporin, this is the second immunosuppressant from the biotech field.
More From This Section
RPG Life Sciences, currently markets four immunosuppressant brands, — Azoran (Azathioprin), Arpimune (Cyclosporin), Mofetyl (Mycophenolate Mofetil) and Imunetoc (Tacrolimus) in India and other emerging markets.
In the oncology space, RPG Life Sciences has launched Daunorubicin, Doxorubicin and Epirubicin and this space contributes 36 per cent to the company's revenues, the release said.
The company has three more biotech molecules which are under development, one of which is expected to be launched in the current financial year.
These products are in the area of oncology and immuno suppression, the release said.